Effects of adding convalescent plasma therapy for treatment of COVID-19 patients with severe and critical symptoms: a descriptive study of 12 cases
Novelty in Biomedicine,
Vol. 9 No. 2 (2021),
10 June 2021
,
Page 39-45
https://doi.org/10.22037/nbm.v9i2.32319
Abstract
Background: Severe symptoms of COVID-19 could be actually life-threatening and fatal. No effective treatment
has been proposed yet. Plasma from COVID19 recovered patients may be effective according to past similar
studies of some other viral infections.
Materials and Methods: This study was conducted at the infectious disease ward of Shahid Labbafi Nejad
Hospital (Tehran, Iran) from 3rd of April 2020 up until 3rd of May 2020. Clinical information for the 12 patients,
before and after receiving convalescent plasma transfusion was obtained from a review of the hospital computer
medical system retrospectively and analyzed.
Results: Out of 12 patients with Covid-19 who received convalescent plasma, 7 patients were male (58.3%)
and 5 were female (41.7%). The mean age of the patients was 52 years. Among them, 50% (n=6), improved
and discharged and the rest of them died. Mean O2 saturation of patients with final outcome of death and
discharged before plasma therapy were 67 (33%) and 77 (83%), respectively, an improvement, defining partial
resolution of lesions of chest CT scan or stop in progression of infiltrations was detected in all of 6 discharged
patients.
Conclusion: Convalescent plasma may have effective role in improving O2 saturation, lymphopenia and CT scan
lesions and also decreasing inflammatory factors of cases with severe manifestations but could not change
prognosis for critically ill patients. Therefore, an early administration of convalescent plasma may be helpful.
- Convalescent Plasma, COVID-19, treatment, severe
How to Cite
References
Cunningham AC,Guh HP, Koh D . Treatment of COVID-19: old tricks for new challenges Critical Care (2020)24:91,https://doi.org/10.1186/s13054-020-2818-6
Janice Hopkins Tanne , Covid-19: FDA approves use of convalescent plasma to treat critically ill patients BMJ 2020;368:m1256
Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis 2005;24:583–91.
Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing highdose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10:676–78.
Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin
Microbiol Infect Dis 2005;24:44–6.
WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease
for transfusion, as an empirical treatment during outbreaks. 2014. http://apps.who.int/iris/rest/ bitstreams/604045/retrieve (accessed Feb 20, 2020).
Shen Ch, Wang Zh, Zhao F, Yang Y, et al; Treatment of 5 Critically ill patients with COVID-19 with convalescent
plasma, JAMA. 2020;323(16):1582-9.
Wang l, C-reactive protein levels in the early stage of COVID-19; Médecine et maladies infectiousness. 2020;50:332-4.
Yan li, Zhang HT, Goncolves J and et al; An interpretable mortality prediction model for COVID-19 patients. Nature Machin e Intelligence. 2020;2:283–8.
Haung G, Kovali AJ, Garber CJ, Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease
Severity; https://wwwnc.cdc.gov/eid/article/26/8/20-1160_article
Tan l, Wang Q, Zhang D and et al; Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study:https://doi.org/10.1038/s41392-020-0148-4
Ruan Q, Yang K, Wang W, Jiang L and et al; Clinical predictors of mortality due to COVID‑ 19 based on an analysis of data of 150 patients from Wuhan, China; Intensive Care Med (2020) 46:846 848https://doi.org/10.1007/s00134-020-05991-x
Haybar H, Kazemnia K, Rahim F, underling chronic
disease and COCID-19 infection: a state of the art review,
Jundishapour J Chronic Dis Care, Online ahead print; 9(2):
e103452. Doi: 10.5812/ggcdc. 103452.
Huang L, Rim MA, Pranata R; Diabetes mellitus is
associated with increased mortality and severity of disease in
COVID-19 pneumonia e A systematic review, metaanalysis,
and meta-regression; Diabetes & Metabolic Syndrome:
Clinical Research & Reviews 14 (2020) 395e403.
Roncon L, Zuin M, Rigatelli G, Zuliani G; Diabetic
patients with COVID-19 infection are at higher risk of ICU
admission and poor short-term outcome; Journal of Clinical
Virology 127 (2020) 104354.
Hung IF, Lung K-C, Yuk Kand et al; Triple combination
of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the
treatment of patients admitted to hospital with COVID-19: an
open-label, randomised, phase 2 trial; Lancet 2020; 395:
–704 Published Online May 8, 2020
https://doi.org/10.1016/ S0140-6736(20)31042-4.
Sallard E, Lescure F-X,Yazdanpanah Y and et al; Type 1
interferons as a potential treatment against COVID-19;
- Abstract Viewed: 319 times
- 1 Downloaded: 254 times